MedPath

Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity

Recruiting
Conditions
Smith-Magenis Syndrome
Epilepsy
Prader-Willi Syndrome
Angelman Syndrome
X Fragile Syndrome
Registration Number
NCT04768803
Lead Sponsor
University Hospital, Toulouse
Brief Summary

A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population. Prader-Willi syndrome is the only genetic obesity identified to date associated with hyperghrelinemia, while ghrelin levels are lower than in controls in other situations of obesity.

The aim of the study is to find out whether the levels of ghrelin, which are abnormally high in PWS throughout life, are also high in these RD when people have hyperphagia and/or overweight.

Detailed Description

A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population. Prader-Willi Syndrome (PWS) and related syndromes (PWS-like) represent the most well-known causes of eating disorders with early and severe obesity. Other known RD with ID have been described as being associated with eating disorders with overweight or obesity, which appear later in adolescence : Angelman's syndrome (approximately 40% of patients are overweight or obese, and 32% of children have hyperphagia), Fragile X syndrome (over 30% are obese), Smith-Magenis syndrome (50 to 60% are obese). Prader-Willi syndrome is the only genetic obesity identified to date associated with hyperghrelinemia, while ghrelin levels are lower than in controls in other situations of obesity.

The aim of the study is to find out whether the levels of ghrelin, which are abnormally high in PWS throughout life, are also high in these pathologies when people have hyperphagia and/or overweight.

The study involves a single visit carried out during a routine follow-up in the CRMR, in which the blood sample will allow the dosage of the ghrelin hormon. The visit will also involves a data collection and some questionnaires.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Patients with one of the following rare diseases associated with : Angelman syndrome, Smith-Magenis syndrome, X Fragile syndrome, rare diseases of the cerebellum, rare epilepsies, PW-like syndromes or other rare diseases with eating disorders
  • Patients aged minimum 3 years and maximum 50 years.
  • Patients with overweight (or obesity) and/or hyperphagic behavior.
Exclusion Criteria
  • Administrative problems: impossibility of giving parents or legal guardians informed information ; no coverage by a Social Security scheme.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Levels of ghrelin in blood sampleDay 1

dosage of ghrelin (pmol /l)

Secondary Outcome Measures
NameTimeMethod
Behavioral disorder descriptionDay 1

Developmental Behavior Checklist-Adult questionnaire for patients over 18 years old

Social vulnerability of parents and / or legal guardiansDay 1

EPICES questionnaire (Assessment of Precariousness and Health Inequalities for the Health Examination Centers).

Burden of parents and / or legal guardiansDay 1

ZBI questionnaire (Zarit Burden Interview).

OvereatingDay 1

eating behavior assessment scale

Family quality of life (for patients under 18)Day1

Parental-Developmental Disabilities Quality of Life questionnaire

Trial Locations

Locations (2)

Tauber

🇫🇷

Toulouse, France

Centre N°1 : 40 Centre de Référence PRADORT Pr Tauber - Toulouse Centre N°2 : 22 Centre de Référence PRADORT Pr Poitou Bernert - Paris La Pitié Salpetrière Centre N°3 : 15 Centre de Référence DI de causes rares Dr Heron - Paris La Pitié Salpêtrière Centr

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath